Previous discussion regarding how difficult it is to produce remdesivir:<p><a href="https://news.ycombinator.com/item?id=22783363" rel="nofollow">https://news.ycombinator.com/item?id=22783363</a>
It's remarkable how a non-randomized study of Hydroxychloroquine is anathema, yet a non-randomized study of Remdesivir that's paid for by its manufacturer and written up by that manufacturer's employee is not. Hmm, I wonder why that is. To top it off, it might actually have the same QT prolongation issues, because some other antivirals have them.<p>That said, politics aside, I hope it works far beyond our wildest expectations so fewer people die.
> enough to supply more than 140,000 patients<p>> the firm has set an “ambitious goal” of producing more than 500,000 treatment courses by October, and 1m by the end of the year<p>So no. Even if this is a cure, the pandemic gets worse before it gets better.
Like the article says, there have been some hopeful anecdotes, but that is a long way from an effective cure and rigorous testing phase. Aka to early to tell.